Clinical trial · Observational
Immune Response in Lung Cancer
NCT01955343CI-TRIAL-00028243IRLCcompletedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This study is designed to evaluate the importance of the immune cells localization (distribution) between malignant tumor islets and surrounding stroma and to investigate the associations between these immune cells as well as cytokines and clinicopathological and prognostic factors of non-small cell lung cancer (NSCLC) patients.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Lung Cancer | Malignant Lung Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (0)
Data not yet available
No intervention recorded.
Design
Arms and outcomes
Arms (2)
- label
- Lung cancer
- description
- Newly diagnosed and untreated non small cell lung cancer patients who underwent surgical resection for NSCLC (pathological stage I-III)
- label
- Control
- description
- Subjects who will have surgery due to recurrent spontaneous pneumothorax Patients without lung cancer or other malignancies
Primary outcomes (1)
- measure
- progression-free survival
- timeFrame
- one year after enrolment to the study
Secondary outcomes (1)
- measure
- overall survival
- timeFrame
- 3 years
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 80 Years
Show eligibility criteria text
Inclusion Criteria: * Eastern Cooperative Oncology Group (ECOG) score of 0-1 * Patients with histologically documented non-small cell lung cancer * Control group - patients without non-small cell lung cancer * Written (signed) Informed Consent to participate in the study Exclusion Criteria: * Any other malignancies within 5 years * Any unstable systemic disease (including active infections, significant cardiovascular disease) * Prior chemotherapy or radiotherapy * Autoimmune disease * Nursing or pregnant women
References
Publications (1)
- DERIVEDJackute J, Zemaitis M, Pranys D, Sitkauskiene B, Miliauskas S, Vaitkiene S, Sakalauskas R. Distribution of M1 and M2 macrophages in tumor islets and stroma in relation to prognosis of non-small cell lung cancer. BMC Immunol. 2018 Jan 24;19(1):3. doi: 10.1186/s12865-018-0241-4. PMID 29361917